Friends of Cancer Research has launched a collaboration that aims to address concerns about the lack of consistency in determining homologous recombination deficiency—HRD—status, its prognostic value, and its use as a predictive biomarker.
Peer review, registries, and evidence-based patient information have taken a hit in Trump’s first 100 days in office.
